Seed · Biotech · London, United Kingdom · Founded 2024 · 2–10 employees
AminoAnalytica is building an AI-driven platform for autonomous protein design, aiming to accelerate drug discovery by predicting and optimizing protein properties at scale. It emerged from a 2024 founding team including ex-Mercedes F1 and Thermo Fisher scholars alongside a computational bionanotechnology lead from Imperial College London, highlighting strong academic and industry pedigree. The startup has secured a Seed round of approximately USD 500 000 via Y Combinator, underscoring early investor confidence and access to one of the most prominent accelerator networks. It is noted for publishing educational tutorials on its AI agent, Amina, demonstrating transparency and community engagement. The platform’s early revenue is estimated at around USD 750 000, indicating initial market traction.*
No open roles listed right now.